SHBG as a breast cancer risk biomarker in premenopausal women? Results from an individual patient's pooled analysis and a meta-analysis

Clicks: 25
ID: 328389
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #74 of 409 articles by views in JNCI Journal of the National Cancer Institute

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 409 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Low levels of sex hormone-binding globulin (SHBG) have been associated with increased breast cancer (BC) risk, particularly in postmenopausal women. Whether this association extends to premenopausal women remains uncertain. We therefore performed an individual-patient pooled analysis and a meta-analysis to evaluate SHBG's role as a biomarker across menopausal status. METHODS: The pooled analysis included women at increased BC risk enrolled in two low-dose tamoxifen trials. The meta-analysis included 11 independent published studies assessing the association of SHBG with BC risk in healthy premenopausal women. RESULTS: Among premenopausal women in the pooled high-risk cohort, SHBG levels above the lowest tertile were associated with a 40% lower hazard of subsequent breast cancer events (HR = 0.60; 95% CI, 0.38-0.96; p = 0.03). In the meta-analysis, comprising 35,167 premenopausal women and 2,302 BC events, the summary estimate in premenopausal women showed a non-significant 8% risk reduction (SOR=0.92; 95% CI, 0.78-1.09). On the other hand, among the seven studies reporting stratified data by menopausal status, postmenopausal women experienced a significant 28% risk reduction (SOR=0.77; 95% CI, 0.69-0.87), with no statistically significant heterogeneity by menopausal status (P = 0.28). CONCLUSIONS: In a selected high-risk population, higher baseline SHBG was associated with fewer subsequent BC events. However, the meta-analysis did not provide statistically significant evidence of an inverse association with breast cancer occurrence in premenopausal women. These findings suggest that SHBG may be a biomarker of subsequent breast events in high-risk settings but do not confirm its role as a risk biomarker in the general premenopausal population.
Reference Key
openalex_W7212244200 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Davide Serrano, Roberta Rizzo, Harriet Johansson, Debora Macis, Valentina Aristarco, Aliana Guerrieri‐Gonzaga, Matteo Lazzeroni, Gaetano Aurilio, Alessio Carbone, Sofia Ramalho, Bernardo Bonanni, Andrea DeCensi, Sara Gandini
Are you one of these authors? Claim your profile
Journal JNCI Journal of the National Cancer Institute
Year 2026
DOI
10.1093/jnci/djag318
URL
https://doi.org/10.1093/jnci/djag318
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.